ATE266646T1 - Phenanthryl-piperazinyl-dicarbonsäure als selective nmda-rezeptor modulierende mittel - Google Patents

Phenanthryl-piperazinyl-dicarbonsäure als selective nmda-rezeptor modulierende mittel

Info

Publication number
ATE266646T1
ATE266646T1 AT00986451T AT00986451T ATE266646T1 AT E266646 T1 ATE266646 T1 AT E266646T1 AT 00986451 T AT00986451 T AT 00986451T AT 00986451 T AT00986451 T AT 00986451T AT E266646 T1 ATE266646 T1 AT E266646T1
Authority
AT
Austria
Prior art keywords
nmda receptor
receptor modulating
phenanthryl
piperazinyl
selective nmda
Prior art date
Application number
AT00986451T
Other languages
English (en)
Inventor
Daniel T Monaghan
David E Jane
Heong Wai Tse
Original Assignee
Univ Bristol
Univ Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bristol, Univ Nebraska filed Critical Univ Bristol
Application granted granted Critical
Publication of ATE266646T1 publication Critical patent/ATE266646T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9466—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00986451T 1999-12-16 2000-12-18 Phenanthryl-piperazinyl-dicarbonsäure als selective nmda-rezeptor modulierende mittel ATE266646T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9929582.6A GB9929582D0 (en) 1999-12-16 1999-12-16 Chemical compounds
PCT/US2000/034137 WO2001044205A2 (en) 1999-12-16 2000-12-18 Phenanthryl piperazinyl dicarboxylic acids as selective nmda receptor modulating agents

Publications (1)

Publication Number Publication Date
ATE266646T1 true ATE266646T1 (de) 2004-05-15

Family

ID=10866322

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00986451T ATE266646T1 (de) 1999-12-16 2000-12-18 Phenanthryl-piperazinyl-dicarbonsäure als selective nmda-rezeptor modulierende mittel

Country Status (7)

Country Link
EP (1) EP1244638B1 (de)
AT (1) ATE266646T1 (de)
AU (1) AU783141B2 (de)
CA (1) CA2395290A1 (de)
DE (1) DE60010755T2 (de)
GB (1) GB9929582D0 (de)
WO (1) WO2001044205A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425540B2 (en) 2004-03-30 2008-09-16 The Hospital For Sick Children Method for modification of NMDA receptors through inhibition of Src
US8003609B2 (en) 2004-03-30 2011-08-23 The Hospital For Sick Children Method for ameliorating pain by modification of NMDA receptors through inhibition of Src
WO2014173900A1 (en) * 2013-04-22 2014-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of epileptic seizures

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
AU696922B2 (en) * 1993-04-20 1998-09-24 Merck & Co., Inc. Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor

Also Published As

Publication number Publication date
WO2001044205A3 (en) 2002-02-21
AU783141B2 (en) 2005-09-29
DE60010755T2 (de) 2005-09-01
EP1244638B1 (de) 2004-05-12
WO2001044205A2 (en) 2001-06-21
AU2268901A (en) 2001-06-25
CA2395290A1 (en) 2001-06-21
EP1244638A2 (de) 2002-10-02
GB9929582D0 (en) 2000-02-09
DE60010755D1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
EP0896533A4 (de) Pentafluorobenzensulfonamiden und analoge
NO933452L (no) Et terapeutisk middel for Parkinson's sykdom
DE60107395D1 (de) 1,5-benzothiazepine und ihre verwendungs als hypolipidämika
SE9903760D0 (sv) New compounds
AU515774B2 (en) Benzopyran derivatives
TR200000671T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler.
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
ES2187025T3 (es) Nuevos agentes quelantes de hierro (iii) activos via oral.
AU4250200A (en) Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
BR1100061A (pt) Composto, processo para a preparação do mesmo, composição e uso dos mesmos
CO4980887A1 (es) Nueva 3,4-diariltiazolina-2-uno o 2-tiono derivados, sus metodos de preparacion y su uso terapeutico
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
ATE266646T1 (de) Phenanthryl-piperazinyl-dicarbonsäure als selective nmda-rezeptor modulierende mittel
NO985202L (no) Anti-heliobacter pylori-preparater inneholdende 1-metylcarbapenemderivater
MX9804828A (es) Benzotiazolona etanaminas biologicamente activas.
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
IT1289979B1 (it) 5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
ATE215934T1 (de) Neue histidinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen freie radikale
ES8200648A2 (es) Procedimiento de preparacion de compuestos opacificantes para radiografia y similares
DK0420224T3 (da) Anthihepatopatisk middel
ATE104313T1 (de) Neue 9-g(a)-hydroxy-3-oxo-4,24(25)-stigmastadien26-s|urederivate,verfahren zur herstellung und heilmittel daraus.
DE69615657D1 (de) Antifungal fusacandine
BR9611805A (pt) Derivados de amino álcool processos para a sua produção e agentes farmacêuticos contendo estes compostos
NO20004685L (no) Nye forbindelser
EA200001157A3 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties